With a strong background in technology and healthcare, the fund manager has successfully executed over 30 deals across North America and Europe. Specializing in early-stage investments, their strategic approach combines an operator-first mindset with data-driven insights. Notable exits have included significant returns from innovative startups in the biotech sector, reflecting a keen understanding of thematic market trends. Their portfolio showcases a commitment to identifying disruptive companies that leverage cutting-edge advancements.